A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
Whether Epitalon raises or lowers cancer risk in people is unknown, because no human study has measured cancer incidence. The concern comes from biology: Epitalon, the tetrapeptide Ala-Glu-Asp-Gly, has been reported to switch on telomerase in cultured human cells, and most cancers depend on telomerase. The reassurance comes from rodent studies, almost all from the group that developed it, reporting fewer or smaller tumours. Neither line has been tested in people, and Epitalon is not an approved medicine in Canada, the US or the EU.

NovaEvum sells Epitalon as research material for laboratory use only. This page is about the evidence, because the cancer question comes up constantly and is usually answered with confidence in one direction or the other. The evidence supports neither. Nothing here is medical, dosing, or therapeutic guidance.
Why does telomerase raise a cancer question at all?
Telomeres are repeated DNA sequences that cap the ends of chromosomes. In most human cells they shorten a little with each division, and when they become short enough the cell stops dividing. Telomerase is the enzyme that rebuilds them. Its catalytic subunit is called TERT.
Two findings from the 1990s frame everything that follows.
Telomerase is switched on in most cancers. Kim and colleagues developed a sensitive assay for telomerase activity and found it in 98 of 100 immortal cell populations and none of 22 mortal ones. It was present in 90 of 101 tumour biopsies representing 12 tumour types, and absent from all 50 normal somatic tissue samples tested (PMID 7605428). A survey a few years later by Shay and Bacchetti reached the same conclusion across essentially every major cancer type. The reading that has held up since is that cancer cells need some way to maintain their telomeres to keep dividing indefinitely, and telomerase is the usual way.
Telomerase alone did not transform normal cells. Bodnar and colleagues introduced the TERT gene into two types of normal human cells. The cells elongated their telomeres, kept dividing for at least 20 doublings beyond their normal limit, and retained a normal karyotype (PMID 9454332). Telomerase extended their lifespan in culture without, in that study, making them cancerous.
Put together: telomerase is close to necessary for most cancers, but it is not by itself sufficient to cause one. That is why "Epitalon activates telomerase" is a reason to ask about cancer risk, not an answer.
There is also human genetic evidence. The Telomeres Mendelian Randomization Collaboration used gene variants associated with telomere length as a natural experiment across 35 cancers. Genetically longer telomeres were generally associated with higher risk of site-specific cancers, most strongly glioma, lung adenocarcinoma, some ovarian cancers, neuroblastoma, bladder cancer and melanoma, while being associated with lower risk of coronary heart disease (PMID 28241208). That is lifelong, inherited telomere length, not a compound taken for a period. It does show that "longer telomeres" is not a uniformly good outcome.
What do the Epitalon telomerase studies report?
There are two papers to know, and they come from different laboratories.
Khavinson 2003. The original claim comes from Vladimir Khavinson's group in St Petersburg. Adding Epitalon to cultures of telomerase-negative human fetal fibroblasts induced expression of the telomerase catalytic subunit, telomerase activity and telomere elongation (PMID 12937682). It is a short report, in one cell type, and it is the basis of most of what is written about Epitalon and ageing.
Al-Dulaimi 2025. Two decades later, an independent group at Brunel University London tested Epitalon in normal epithelial cells, fibroblasts and two breast cancer cell lines, 21NT and BT474 (PMID 40908429). In the normal cells, telomere length increased with concentration, along with TERT messenger RNA and telomerase activity. In the cancer cell lines, telomeres also lengthened, but through a different route, alternative lengthening of telomeres (ALT), a telomerase-independent mechanism some cancers use. Only a minor increase in ALT activity was seen in the normal cells.
The second paper is the first independent confirmation of the telomere effect in cells. It also shows telomere lengthening in cancer cell lines. That is a cell-culture result and does not show that Epitalon promotes tumours. It does mean the question cannot be waved away.
What did the rodent tumour studies find?
The tumour data come almost entirely from Vladimir Anisimov's group at the Institute of Oncology in St Petersburg, working with Khavinson.
| Study | Animals | Reported tumour result |
|---|---|---|
| Anisimov 2002, PMID 12209581 | Female HER-2/neu transgenic mice, prone to breast tumours | Fewer cumulative tumours and smaller maximum tumour size; lung metastases smaller but not fewer |
| Anisimov 2003, PMID 14501183 | Female SHR mice, 54 per group, treated for life | No change in total spontaneous tumour incidence; less leukaemia; no change in mean lifespan |
| Kossoy 2006, PMID 16634527 | Female C3H/He mice, 6.5 months | Fewer mice with malignant tumours; metastases in 3 of 9 tumour-bearing controls and none in treated mice |
| Vinogradova 2007, PMID 18856211 | Female rats under three lighting regimes | No effect on tumours under standard or constant light; fewer tumours under natural northern light |
Three features of this table matter more than any single row.
No study reported an increase in tumours. That is a genuine finding and it is the basis of the claim that Epitalon is "anti-cancer". It is also a finding from small groups, short or single studies, and one research network.
The results are not consistent. One study found no effect on total tumour incidence. Another found an effect under one lighting condition and not the other two. The striking metastasis result in the C3H/He study rests on three animals out of nine.
A related peptide went the other way. In the HER-2/neu study, the comparison dipeptide Vilon (Lys-Glu), from the same group, increased the incidence of mammary cancer and the number of tumours (PMID 12209581). Short peptides from this programme are not uniformly protective, even in the hands of the people who make them.
Why is neither risk nor protection established in people?
Because the experiments that would answer the question have not been done, and the ones that have been done cannot substitute for them.
Mice are a poor model for telomere biology. Laboratory mice have much longer telomeres than humans and express telomerase in more of their tissues. A compound that changes telomerase activity may matter very differently in a species where telomeres are rarely the limit.
The groups are too small to see rare outcomes. A rise in a cancer that affects a few per cent of animals would be invisible in groups of a few dozen. Absence of an increase in these studies is weak evidence of absence.
Cancer takes years in people. No human study of Epitalon has followed participants for cancer incidence. A 2026 narrative review by Jain and colleagues found that human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa, that long-term safety data remain inadequate, and that oncologic uncertainties were unresolved following a 2026 FDA advisory review (PMID 42884164).
Products in circulation are not the compound in the papers. Analysts at Belgium's Scientific Institute of Public Health identified Epitalon in two illegal pharmaceutical preparations (Vanhee and colleagues, PMID 25535022). Unregulated material adds an identity and contamination question on top of the pharmacology.
| Claim you will see | What supports it | What it lacks |
|---|---|---|
| "Epitalon activates telomerase" | Two cell-culture papers, one independent | Any human tissue measurement |
| "So it causes cancer" | Telomerase is active in most cancers; telomere lengthening seen in two breast cancer cell lines | Any tumour increase in animals or people |
| "It prevents cancer" | Small rodent studies from one network reporting fewer or smaller tumours | Replication by another group; any human data |
The one-laboratory problem
Nearly all Epitalon research, telomerase, pineal and tumour work alike, comes from Khavinson's and Anisimov's groups and their collaborators. The pineal and melatonin side of that programme, and what single-group concentration means for reading it, is covered in Epithalon, the pineal gland and melatonin. The general case for why independent replication matters is in how to read a peptide study.
The Brunel paper is the exception, and it is worth noticing what independent work found: the telomere effect in normal cells held up, and the cancer cell lines lengthened their telomeres too.
Where the evidence stands
Evidence stage. Cell culture for the telomerase effect, with one independent confirmation. Rodent studies for tumour outcomes, from one network, small and mixed. No human study with a cancer endpoint; ClinicalTrials.gov lists no trial measuring cancer incidence.
Regulatory status. Not an approved medicine in Canada, and not approved by the FDA or the EMA. See what Health Canada's rules mean for research peptides.
Sold here as research material only. Epitalon is supplied for laboratory use, not for human or veterinary use. For mitochondrial and ageing-adjacent compounds with their own, different limits, see MOTS-c, the mitochondrial peptide.
Frequently asked questions
Does Epitalon cause cancer? There is no evidence that it does, and no evidence that it does not, in people. No human study has measured cancer incidence. Rodent studies from the developing group reported no increase in tumours, but they were small. Telomerase activation in cells, plus telomere lengthening seen in two breast cancer cell lines, keeps the question open.
Can Epitalon prevent cancer? That has not been shown. The supporting studies are small rodent experiments from one research network, with mixed results: fewer or smaller tumours in some, no change in total tumour incidence in another, and an effect under only one of three lighting conditions in a rat study. None has been replicated independently or tested in people.
Why is telomerase activation linked to cancer? Most cancer cells need a way to keep their telomeres from running out so they can divide indefinitely, and telomerase is the usual way. It is found in about nine in ten tumour samples and is largely silent in normal adult tissues. Telomerase alone did not make normal cells cancerous in culture, so activation is a reason to ask, not proof of harm.
Has anyone outside Russia studied Epitalon and telomeres? Yes, one group. A 2025 study from Brunel University London found telomere lengthening in normal human cells through telomerase, and lengthening in two breast cancer cell lines through a telomerase-independent route called ALT. It is cell culture and says nothing directly about tumour risk in animals or people.
Is Epitalon approved anywhere for cancer or ageing? It is not approved by Health Canada, the FDA or the EMA for any use. Belgian public-health analysts have found it in illegal pharmaceutical preparations. NovaEvum sells it only as research material for laboratory use, and this page is about the evidence only.
Selected Research References
- Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011-2015. pubmed.ncbi.nlm.nih.gov/7605428
- Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349-352. pubmed.ncbi.nlm.nih.gov/9454332
- Haycock PC, Burgess S, Nounu A, et al. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncology. 2017;3(5):636-651. pubmed.ncbi.nlm.nih.gov/28241208
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. pubmed.ncbi.nlm.nih.gov/12937682
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. pubmed.ncbi.nlm.nih.gov/40908429
- Anisimov VN, Khavinson VK, Provinciali M, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 2002;101(1):7-10. pubmed.ncbi.nlm.nih.gov/12209581
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. pubmed.ncbi.nlm.nih.gov/14501183
- Kossoy G, Anisimov VN, Ben-Hur H, et al. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006;20(2):253-257. pubmed.ncbi.nlm.nih.gov/16634527
- Jain A, Gallacher DM, Issa MA, et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. International Journal of Molecular Sciences. 2026;27(19):8922. pubmed.ncbi.nlm.nih.gov/42884164
- Vanhee C, Moens G, Van Hoeck E, et al. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and retinitis pigmentosa in two illegal pharmaceutical preparations. Drug Testing and Analysis. 2015;7(3):259-264. pubmed.ncbi.nlm.nih.gov/25535022
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
